On January 5, 2006, the National Cancer Institute (NCI) released a clinical announcement concerning recommended treatment for advanced ovarian cancer.
Based on the results of eight phase III clinical trials, the NCI is encouraging doctors to follow surgery with a combination of two drug-delivery methods: intravenous (by vein) and intraperitoneal (directly into the abdomen). The combined approach, though more toxic, extends overall survival for women with advanced ovarian cancer by about a year compared to intravenous delivery alone.
Epithelial ovarian carcinoma is the leading cause of death from gynecologic malignancies in the developed world. To date, no effective screening regimen for ovarian cancer has been identified. More than half of women with ovarian cancer present with advanced-stage disease (stage III or IV) at the time of diagnosis.
For more information, please see the links in this and the following sections.
- NCI Issues Clinical Announcement for Preferred Method of Treatment for Advanced Ovarian Cancer
(Posted: 01/04/2006) - NCI today issued an announcement encouraging treatment with anticancer drugs via two methods, after surgery, for women with advanced ovarian cancer. The combined methods, which deliver drugs into a vein and directly into the abdomen, extend overall survival for women with advanced ovarian cancer by about a year. Questions and Answers
- NCI Clinical Announcement: Intraperitoneal Chemotherapy for Ovarian Cancer
The Jan. 5, 2006, NCI clinical announcement concerning the preferred method of treatment for advanced ovarian cancer, based on the results of trials investigating the use of intraperitoneal administration of anticancer drugs after surgery.